Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi AppTec Acquires HD Biosciences, a Biologics CRO

publication date: Jan 20, 2017
WuXi AppTec, China's largest CRO/CMO, has acquired Shanghai's HD Biosciences. Founded in 2002, HD Bio is a pre-clinical CRO that specializes in biologic drug discovery. WuXi said HD Bio will strengthen its biologics R&D capability from target validation to lead discovery and optimization. In 2016, HD Bio opened an expanded lab in Shanghai's Zhangjiang Hi-Tech Park, and it has a US lab in San Diego. It completed an A venture round in 2008 led by Morningside with Lilly Asian Ventures and Pfizer Venture Investments joining. The financial details of the WuXi-HD Bio acquisition were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital